Aspira Women's Health Files 8-K with Material Agreement

TL;DR

Aspira Women's Health filed an 8-K on Aug 2nd for a material agreement. Check it out.

AI Summary

On August 2, 2024, Aspira Women's Health Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.

Why It Matters

This filing indicates a significant business event or financial update for Aspira Women's Health Inc., which could impact investors and stakeholders.

Risk Assessment

Risk Level: low — This is a standard 8-K filing reporting a material definitive agreement and financial statements, not indicating immediate operational or financial distress.

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• August 02, 2024 (date) — Date of earliest event reported
• Vermillion, Inc. (company) — Former company name
• Ciphergen Biosystems Inc (company) — Former company name
• Abiotic Systems (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• Austin, Texas (location) — Business address

FAQ

From the Filing

0000950170-24-090145.txt : 20240802 0000950170-24-090145.hdr.sgml : 20240802 20240802172654 ACCESSION NUMBER: 0000950170-24-090145 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240802 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240802 DATE AS OF CHANGE: 20240802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 241172381 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 awh-20240802.htm 8-K 8-K 0000926617 false 0000926617 2024-08-02 2024-08-02   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2024     Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           12117 Bee Caves Road Building III Suite 100   Austin , Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 1.01 Entry into a Material Definitive Agreement. On August 2, 2024, Aspira Women’s Health Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ ATM Agreement ”) with H.C. Wainwright & Co., LLC (“ Wainwright ”), to sell shares of our common stock, par value $0.001 per share, (the “ Shares ”) having an aggregat